Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer-Reference-Cited by-同舟云学术

Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer

Published:2024-06-30 Issue:3 Volume:6 Page:199-203
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Noda Michio¹,Kawai Taketo¹,Hagiwara Kanade¹,Yoshida Takahiro¹,Yanagida Kazuki¹,Tokura Yuumi¹,Yoshimura Itsuki¹,Kaneko Tomoyuki¹,Nakagawa Tohru¹

Affiliation:

1. Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Link

https://www.jstage.jst.go.jp/article/ghm/6/3/6_2024.01019/_pdf

Reference16 articles.

1. 1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73:17-48.

2. 2. Foundation for Promotion of Cancer Research. Cancer statistics 2023 in Japan. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2023.pdf (accessed February 27, 2024). (in Japanese)

3. 3. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016; 117:102-109.

4. 4. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009; 115:3437-3445.

5. 5. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377:352-360.